

INTEGRA LIFESCIENCES HOLDINGS CORP

Form 8-K

June 06, 2007

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 6, 2007
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)**

Delaware (State or other jurisdiction of incorporation or organization)	0-26224 (Commission File Number)	51-0317849 (I.R.S. Employer Identification No.)
-------------------------------------------------------------------------------	-------------------------------------	----------------------------------------------------

311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

ITEM 8.01. OTHER EVENTS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

SIGNATURES

Exhibit Index

EX-99.1: PRESS RELEASE

Table of Contents

ITEM 8.01. OTHER EVENTS.

Private Offering

In a press release issued on June 6, 2007, Integra LifeSciences Holdings Corporation (the Company) announced the pricing of its offering of \$150 million aggregate principal amount of senior convertible notes due 2010 and \$150 million aggregate principal amount of senior convertible notes due 2012 (together, the notes) in a private placement, subject to market conditions and other factors. The Company has granted the initial purchasers of the notes options to purchase up to an additional \$15 million aggregate principal amount of each series of notes, in each case within 13 days of the initial issuance of the notes.

A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference, and is being filed pursuant to Rule 135c under the Securities Act of 1933, as amended.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit Number Description of Exhibit

99.1 Press release issued by Integra LifeSciences Holdings Corporation dated June 6, 2007

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: June 6, 2007

By: /s/ Stuart M. Essig
Stuart M. Essig
President and Chief Executive Officer

Table of Contents

Exhibit Index

Exhibit Number	Description of Exhibit
99.1	Press release issued by Integra LifeSciences Holdings Corporation dated June 6, 2007